{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T09:50:33Z","timestamp":1772013033230,"version":"3.50.1"},"reference-count":75,"publisher":"Informa UK Limited","issue":"4","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2018,4,3]]},"DOI":"10.1080\/03007995.2017.1419171","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T08:12:46Z","timestamp":1513843966000},"page":"711-723","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":28,"title":["Abuse-deterrent opioids: an update on current approaches and considerations"],"prefix":"10.1080","volume":"34","author":[{"suffix":"Jr","given":"Joseph V.","family":"Pergolizzi","sequence":"first","affiliation":[{"name":"NEMA Research, Inc., Naples, FL, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert B.","family":"Raffa","sequence":"additional","affiliation":[{"name":"University of Arizona College of Pharmacy, Tucson, AZ, USA;"},{"name":"Temple University School of Pharmacy, Philadelphia, PA, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"suffix":"Jr","given":"Robert","family":"Taylor","sequence":"additional","affiliation":[{"name":"NEMA Research, Inc., Naples, FL, USA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Vacalis","sequence":"additional","affiliation":[{"name":"CaroMont Family Medicine-Gastonia, Gastonia, NC, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2018,1,10]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1508490"},{"key":"CIT0002","author":"Vacalis SE.","year":"2016","journal-title":"Physicians Weekly"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6626a4"},{"key":"CIT0004","first-page":"A1","author":"Hughes A","year":"2016","journal-title":"NSDUH Data Review"},{"key":"CIT0005","unstructured":"Centers for Disease Control and Prevention. Prescription overdose data. Atlanta, GA; 2017. Available online at: https:\/\/www.cdc.gov\/drugoverdose\/data\/overdose.html [Last accessed 29 September 2017]"},{"key":"CIT0006","volume-title":"Center for Behavioral Health Statistics and Quality: Substance Abuse and Mental Health Services Administration","author":"Substance Abuse and Mental Health Services Administration.","year":"2017"},{"key":"CIT0007","first-page":"1","volume":"17","author":"Alexander L","year":"2014","journal-title":"Pharmacy Times"},{"key":"CIT0008","volume-title":"Abuse-deterrent opioids - evaluation and labeling: guidance for industry","author":"U.S. Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research.","year":"2015"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1186\/1477-7517-6-8"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2011.05.014"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.01.039"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.2217\/pmt-2015-0005"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2009.00672.x"},{"key":"CIT0014","unstructured":"US Food and Drug Administration. FDA News Release. FDA requests removal of Opana ER for risks related to abuse. 2017. Silver Spring, MD. Available online at: https:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm562401.htm [Last accessed 25 June 2017]"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2017.9205"},{"key":"CIT0016","volume-title":"OxyContin (oxycodone hydrochloride) extended-release tablets","year":"2015"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.235"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa1406143"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1177\/0269881113493364"},{"key":"CIT0020","volume-title":"Targiniq\u2122 ER (oxycodone hydrochloride and naloxone hydrochloride) extended-release tablets","year":"2016"},{"key":"CIT0021","volume-title":"Troxyca\u00ae ER (oxycodone hydrochloride and naltrexone hydrochloride) extended-release capsules","year":"2016"},{"key":"CIT0022","first-page":"1077","volume":"18","author":"Setnik B","year":"2017","journal-title":"Pain Med"},{"key":"CIT0023","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.552"},{"key":"CIT0024","doi-asserted-by":"publisher","DOI":"10.3109\/00952990.2016.1167215"},{"key":"CIT0025","volume-title":"Xtampza\u00ae ER (oxycodone) extended-release capsules","year":"2016"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12834"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.833"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2014.0211"},{"key":"CIT0029","first-page":"1112","volume":"17","author":"Webster LR","year":"2016","journal-title":"Pain Med"},{"key":"CIT0030","volume-title":"RoxyBond\u2122 (oxycodone hydrochloride) tablets","year":"2017"},{"key":"CIT0031","volume-title":"Hysingla\u2122 ER (hydrocodone bitartrate) extended-release tablets","year":"2014"},{"key":"CIT0032","first-page":"1278","volume":"18","author":"Harris SC","year":"2017","journal-title":"Pain Med"},{"key":"CIT0033","first-page":"820","volume":"17","author":"Harris SC","year":"2016","journal-title":"Pain Med"},{"key":"CIT0034","volume-title":"Vantrela\u2122 ER package insert (hydrocodone bitartrate) extended-release tablets [package insert]","year":"2017"},{"key":"CIT0035","unstructured":"Farber R, Rae S. This week in FDA vs Biotech Part I, will Teva\u2019s Vantrela get abuse-deterrent label? Market Exclusive: Weekly Biotech Report; 2016. Available online at: https:\/\/marketexclusive.com\/weeklybiotechreportcoveringvantrela\/ [Last accessed 26 June 2017]"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1093\/pm\/pnw122"},{"key":"CIT0037","volume-title":"(morphine sulfate) extended-release tablets","author":"Arymo ER","year":"2017"},{"key":"CIT0038","first-page":"898","volume":"18","author":"Smith MD","year":"2017","journal-title":"Pain Med"},{"key":"CIT0039","first-page":"1695","volume":"18","author":"Webster LR","year":"2017","journal-title":"Pain Med"},{"key":"CIT0040","volume-title":"Embeda\u00ae (morphine sulfate and naltrexone hydrochloride) extended-release capsules","year":"2014"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/952082"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.5055\/jom.2013.0155"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12148"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.2165\/11530800-000000000-00000"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.2165\/11593390-000000000-00000"},{"key":"CIT0046","volume-title":"MorphaBond\u2122 ER (morphine sulfate) extended-release tablets","year":"2017"},{"key":"CIT0047","first-page":"1303","volume":"18","author":"Webster LR","year":"2017","journal-title":"Pain Med"},{"key":"CIT0048","volume-title":"MorphaBond new drug application: Clinical pharmacology and biopharmaceutics review","author":"Center for Drug Evaluation and Research.","year":"2015"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.390"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3522"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.09.018"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1002\/pds.3658"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.3111\/13696998.2014.897628"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2012.08.008"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2016.06.009"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2013.04.011"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.1097\/AJP.0000000000000426"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2014.3043"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.1177\/2042098615569726"},{"key":"CIT0060","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2016.01.168"},{"key":"CIT0061","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12489"},{"key":"CIT0062","volume-title":"Abuse-deterrent opioids: final evidence report","author":"Institute for Clinical and Economic Review.","year":"2017"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2016.22.4.347"},{"key":"CIT0064","volume-title":"Societal cost savings from abuse deterrent formulations for prescription opioids in Canada","author":"Skinner BJ.","year":"2017"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1111\/j.1526-4637.2006.00254.x"},{"key":"CIT0066","volume-title":"AMA education center","author":"American Medical Association.","year":"2017"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167499"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.rr6501e1"},{"key":"CIT0069","volume-title":"AMA wire: what phsyicians are saying about the new CDC opioid guidelines","author":"American Medical Association.","year":"2016"},{"key":"CIT0070","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/pds.3708","volume":"24","author":"Coplan PM","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2015.0914"},{"key":"CIT0072","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2014.915803"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1111\/pme.12295"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.02.038"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.2147\/JPR.S129553"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2017.1419171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,6]],"date-time":"2020-09-06T16:16:10Z","timestamp":1599408970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2017.1419171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,10]]},"references-count":75,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,4,3]]}},"alternative-id":["10.1080\/03007995.2017.1419171"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2017.1419171","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,10]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2017-10-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2017-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-01-10","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}